BRIEF—Ono brings Taiwan first I-O therapy for liver cancer

The Taiwanese business of Japan’s Ono Pharma has been approved to market Opdivo (nivolumab) to treat hepatocellular carcinoma patients in the second-line setting.

The label expansion clears the way for Ono to offer the first immuno-oncological therapy for this indication in Taiwan.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, leading to an estimated 10,000 annual diagnoses and 8,300 deaths per year in Taiwan.